Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Chronic Hepatitis C Virus Infection
Interventions
DRUG

SOF plus (OBV/PTV/r) plus RBV

They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.

Trial Locations (1)

Unknown

Beni-Suef University, Banī Suwayf

All Listed Sponsors
lead

Beni-Suef University

OTHER

NCT04391985 - Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients | Biotech Hunter | Biotech Hunter